Aliskiren, the future of renin–angiotensin system blockade?

References

• Reid IA, The renin–angiotensin system, physiology, pathophysiology and pharmacology. Adv. Physiol. Educ.275, 236–245 (1998).
   Google Scholar
• Müller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin. J. Am. Soc. Nephrol.1(2), 221–228 (2006).
   PubMed Web of Science ®Google Scholar
• Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J. Hypertens.23(Suppl.), S9–S17 (2005).
   Google Scholar
• Staessen Jan A, Li Y, Richart T. Oral renin inhibitors. Lancet368(9545), 1449–1456 (2006)
   PubMed Web of Science ®Google Scholar
• Wood JM, Maibaum J, Rahuel J et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun.308, 698–705 (2003).
   PubMed Web of Science ®Google Scholar
• Rigel DF, Fu F, Li S et al. The renin inhibitor aliskiren is a potent and long-acting antihypertensive in double transgenic rats expressing human renin and angiotensinogen genes. J. Am. Coll. Cardiol.43(Suppl. A), 483A (2004).
   PubMed Web of Science ®Google Scholar
• Pilz B, Shagdarsuren E, Wellner M et al. Aliskiren, a human renin activity inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension46, 569–576 (2005).
   PubMed Web of Science ®Google Scholar
• Fiebeler A, Shagdarsuren E, Pilz B et al. Low dose renin inhibitor and AT1 receptor blocker ameliorate angiotensin II-induced end-organ damage despite persistence of hypertension. Presented at Renal Week, PA, USA (2005).
   Google Scholar
• Feldman DL, Jin L, Miserendino-Moltini R et al. The renin inhibitor aliskiren ameliorates hypertensive diabetic nephropathy in transgenic (mRen-2)27 (Ren-2) rats. Presented at Renal Week, PA, USA (2005).
   Google Scholar
• Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren, where are we now and where are we going? J. Hypertens.24(2), 243–256 (2006).
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Limoges D, Yeh C et al. PIII-23Aliskiren, an orally effective renin inhibitor, shows dose-linear pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther.79(2), 64 (2006).
   Google Scholar
• Nussberger J, Wuerzner G, Jensen C et al. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100), comparison with enalapril. Hypertension39, E1–E8 (2002).
   PubMed Web of Science ®Google Scholar
• Zhao C, Vaidyanathan S, Yeh CM, Maboudian M, Dieterich HA. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with Type 2 diabetes mellitus. Clin. Pharmacokinet.45(11), 1125–1134 (2006).
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Jin Y, Schiller H et al. Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro. Basic Clin. Pharmacol. Toxicol.47, 192–200 (2007).
   Google Scholar
• Vaidyanathan S, Valencia J, Kemp C et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int. J. Clin. Pract.60(11), 1343–1356 (2006).
   PubMed Web of Science ®Google Scholar
• Dieterle W, Corynen S, Vaidyanathan S et al. Pharmacokinetic interaction of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int. J. Clin. Pharm. Ther.43, 527–535 (2005).
   PubMed Web of Science ®Google Scholar
• Dieterich H, Kemp C, Vaidyanathan S et al. PIII-24Aliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteers. Clin. Pharmacol. Ther.79, 64 (2006).
   Web of Science ®Google Scholar
• Dieterich H, Kemp C, Vaidyanathan S et al. Pharmacokinetic interaction of the oral renin inhibitor aliskiren with hydrochlorothiazide in healthy volunteers. Clin. Pharmacol. Ther.79, 12 (2006).
   Web of Science ®Google Scholar
• Azizi M, Ménard J, Bissery A et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J. Am. Soc. Nephrol.15, 3126–3133 (2004).
   PubMed Web of Science ®Google Scholar
• Pool J, Gradman A, Kolloch R et al. Aliskiren, a novel renin inhibitor, provides long-term suppression of the renin system, when used alone or in combination with hydrochlorothiazide in the treatment of hypertension. World Congress of Cardiology, Barcelona, Spain (2006) (Abstract P790).
   Google Scholar
• Villamil A, Chrysant SG, Calhoun D et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J. Hypertens.25, 217–226 (2007).
   PubMed Web of Science ®Google Scholar
• Kilo C, Taylor A, Tschoepe D et al. Aliskiren, a novel renin inhibitor for treatment of hypertension, enhances renin system suppression by reducing plasma renin activity alone or in combination with ramipril in patients with diabetes. Eur. Heart J.25(Suppl.), 118 (2006) (Abstract P789).
   Google Scholar
• Sica D, Gradman A, Lederballe O et al. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of hypertension. Eur. Heart J.25(Suppl.), 121 (2007) (Abstract P797).
   Google Scholar
• Brookes L. New data on first-in-class oral renin inhibitor, aliskiren. Medscape conference coverage of the american society of hypertension 21st annual scientific meeting and exposition. NY. Medscape Cardiology, NY, USA (2006).
   Google Scholar
• Munger MA, Drummond W, Essop MR et al. Aliskiren as add-on to amlodipine provides significant additional blood pressure lowering without increased oedema associated with doubling the amlodipine dose. Eur. Heart J.25(Suppl.), 117. (Abstract P784) (2006).
   Google Scholar
• Uresin Y, Taylor AA. Renin inhibitor aliskiren in combination with ACE inhibitor in diabetic patients with hypertension. Presented at: The European Meeting on Hypertension. Madrid, Spain 12–16 June 2006.
   Google Scholar
• Uresin Y, Taylor A, Kilo C et al. Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. J. Hypertens.24(Suppl. 4), S82 (2006) (Abstract P4.269).
   Google Scholar
• O’Brien E, Barton J, Nussberger J et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension49, 276–284 (2007).
   PubMed Web of Science ®Google Scholar
• Herron J, Mitchell J, Oh B et al. The novel renin inhibitor aliskiren is not associated with rebound effects on blood pressure or plasma renin activity following treatment withdrawal. J. Clin. Hypertens.8(5 Suppl. A) A86–A87 (2006).
   Google Scholar
• Kjeldsen SE. outcomes studies. In: European cardiovascular disease (Issue II). Touch Briefings, London, UK (2006).
   Google Scholar
• Stanton A, Jensen C, Nussberger J, O’Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor aliskiren. Hypertension42, 1137–1143 (2003).
   PubMed Web of Science ®Google Scholar
• Gradman AH, Schmieder RE, Lins RL et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation111, 1012–1018 (2005).
   PubMed Web of Science ®Google Scholar
• Gradman AH, Schmieder RE, Lins RL, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides antihypertensive efficacy and placebo-like tolerability similar to an AT1-receptor blocker in hypertensive patients. Am. J. Hypertens.17(5 Pt 2), 108A (2004).
   Google Scholar
• Oh BH, Mitchell J, Herron JER, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J. Am. Coll. Cardiol.49, 1157–1163 (2007).
   PubMed Web of Science ®Google Scholar
• Oparil S, Yarows S, Patel S et al. The direct renin inhibitor aliskiren in combination with the angiotensin receptor blocker valsartan provides additional blood pressure-lowering effects compared with either agent alone in patients with hypertension. Poster presented at American College of Cardiology 2007 (2005).
   Google Scholar
• Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol. Rev.52, 11–34 (2000).
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet369(9568), 1208–1219 (2007).
   PubMed Web of Science ®Google Scholar
• Alderman MH, Ooi WL, Cohen H et al. Plasma renin activity, a risk factor for myocardial infarction in hypertensive patients. Am. J. Hypertens.10, 1–8 (1997).
   PubMed Web of Science ®Google Scholar
• Anan F, Takahashi N, Ooie T et al. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. Eur. J. Clin. Pharmacol.61, 353–359 (2005).
   PubMed Web of Science ®Google Scholar
• Micah L, Thorp DO. Diabetic nephropathy: common questions. MPH Lake road nephrology clinic Milwaukie, Oregon (2005).
   Google Scholar
• Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensinII production and cellular responses to renin. J. Clin. Invest.109, 1417–1427 (2002).
   PubMed Web of Science ®Google Scholar
• Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N. Engl. J. Med.312, 1412–1417 (1985).
   PubMed Web of Science ®Google Scholar
• Davies L, Fulcher GR, Atkins A et al. The relationship of prorenin values to microvascular complications in patients with insulin dependent diabetes mellitus. J. Diabetes Complicat.13, 45–51 (1999).
   PubMed Web of Science ®Google Scholar
• Chiarelli F, Pomilio M, De Luca FA, Vecchiet J, Verrotti A. Plasma prorenin levels may predict persistent microalbuminuria in children with diabetes. Int. J. Pediatr. Nephrol.16(2), 116–120 (2001).
   Google Scholar
• Kjeldsen SE. Direct renin inhibition with focus on aliskiren and cardiovascular outcome studies In: European Cardiovascular Disease (Issue II). Touch Briefings, London, UK (2006).
   Google Scholar